PCIDB

KNApSAcK Metabolite C00032635

Metabolite

KNApSAcK Entry

id C00032635
Name 3-Hydroxytyrosol / 3,4-Dihydroxyphenethyl alcohol
CAS RN 10597-60-1
Standard InChI InChI=1S/C8H10O3/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,9-11H,3-4H2
Standard InChI (Main Layer) InChI=1S/C8H10O3/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,9-11H,3-4H2

Cluster

Phytochemical cluster No. 6
KCF-S cluster No. 1114

Link

ChEMBL

By standard InChI CHEMBL1950045
By standard InChI Main Layer CHEMBL1950045

KEGG

By LinkDB

CTD

By CAS RN C005975

Human Protein / Gene in interaction

CTD interaction (38)

compound gene gene name gene description interaction interaction type form reference
pmid
C005975 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 3,4-dihydroxyphenylethanol results in increased phosphorylation of BCL2 protein increases phosphorylation
protein 12482581
C005975 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) 3,4-dihydroxyphenylethanol inhibits the reaction [Acrylamide results in increased activity of CASP3 protein] decreases reaction
/ increases activity
protein 21777647
C005975 6352 CCL5
D17S136E
RANTES
SCYA5
SIS-delta
SISd
TCP228
eoCP
chemokine (C-C motif) ligand 5 [Vitamin E co-treated with Quercetin co-treated with kaempferol co-treated with 3,4-dihydroxyphenylethanol] results in decreased expression of CCL5 mRNA affects cotreatment
/ decreases expression
mRNA 16797527
C005975 993 CDC25A
CDC25A2
cell division cycle 25A (EC:3.1.3.48) 3,4-dihydroxyphenylethanol results in decreased expression of CDC25A mRNA decreases expression
mRNA 12482581
C005975 37618 [Vitamin E co-treated with Quercetin co-treated with kaempferol co-treated with 3,4-dihydroxyphenylethanol] results in increased expression of CYCB mRNA affects cotreatment
/ increases expression
mRNA 16797527
C005975 1958 EGR1
AT225
G0S30
KROX-24
NGFI-A
TIS8
ZIF-268
ZNF225
early growth response 1 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [3,4-dihydroxyphenylethanol results in increased expression of EGR1 mRNA] decreases reaction
/ increases expression
mRNA 12482581
C005975 1958 EGR1
AT225
G0S30
KROX-24
NGFI-A
TIS8
ZIF-268
ZNF225
early growth response 1 3,4-dihydroxyphenylethanol results in increased expression of EGR1 mRNA increases expression
mRNA 12482581
C005975 1958 EGR1
AT225
G0S30
KROX-24
NGFI-A
TIS8
ZIF-268
ZNF225
early growth response 1 3,4-dihydroxyphenylethanol results in increased expression of EGR1 protein increases expression
protein 12482581
C005975 1958 EGR1
AT225
G0S30
KROX-24
NGFI-A
TIS8
ZIF-268
ZNF225
early growth response 1 SB 203580 promotes the reaction [3,4-dihydroxyphenylethanol results in increased expression of EGR1 mRNA] increases expression
/ increases reaction
mRNA 12482581
C005975 10922 FASTK
FAST
Fas-activated serine/threonine kinase (EC:2.7.11.8) 3,4-dihydroxyphenylethanol results in increased expression of FASTK mRNA increases expression
mRNA 12482581
C005975 1647 GADD45A
DDIT1
GADD45
growth arrest and DNA-damage-inducible, alpha 3,4-dihydroxyphenylethanol results in increased expression of GADD45A mRNA increases expression
mRNA 12482581
C005975 2936 GSR
glutathione reductase (EC:1.8.1.7) 3,4-dihydroxyphenylethanol inhibits the reaction [Acrylamide results in increased activity of GSR protein] decreases reaction
/ increases activity
protein 21777647
C005975 3383 ICAM1
BB2
CD54
P3.58
intercellular adhesion molecule 1 3,4-dihydroxyphenylethanol inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] decreases reaction
/ increases expression
protein 12615669
C005975 3567 IL5
EDF
IL-5
TRF
interleukin 5 (colony-stimulating factor, eosinophil) [Vitamin E co-treated with Quercetin co-treated with kaempferol co-treated with 3,4-dihydroxyphenylethanol] results in decreased expression of IL5 mRNA affects cotreatment
/ decreases expression
mRNA 16797527
C005975 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) [Vitamin E co-treated with Quercetin co-treated with kaempferol co-treated with 3,4-dihydroxyphenylethanol] results in decreased expression of IL6 mRNA affects cotreatment
/ decreases expression
mRNA 16797527
C005975 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene 3,4-dihydroxyphenylethanol results in increased expression of JUN mRNA increases expression
mRNA 12482581
C005975 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene 3,4-dihydroxyphenylethanol results in increased expression of JUN protein increases expression
protein 12482581
C005975 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene 3,4-dihydroxyphenylethanol results in increased expression of JUN protein modified form increases expression
protein 12482581
C005975 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) 3,4-dihydroxyphenylethanol results in increased expression of MAPK1 protein modified form increases expression
protein 12482581
C005975 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) 3,4-dihydroxyphenylethanol results in increased expression of MAPK3 protein modified form increases expression
protein 12482581
C005975 4318 MMP9
CLG4B
GELB
MANDP2
MMP-9
matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) (EC:3.4.24.35) 3,4-dihydroxyphenylethanol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA] decreases reaction
/ increases expression
mRNA 22595400
C005975 4318 MMP9
CLG4B
GELB
MANDP2
MMP-9
matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) (EC:3.4.24.35) 3,4-dihydroxyphenylethanol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein] decreases reaction
/ increases secretion
protein 22595400
C005975 4779 NFE2L1
LCR-F1
NRF1
TCF11
nuclear factor, erythroid 2-like 1 3,4-dihydroxyphenylethanol inhibits the reaction [Acrolein results in decreased expression of NFE2L1 mRNA] decreases expression
/ decreases reaction
mRNA 20938484
C005975 4779 NFE2L1
LCR-F1
NRF1
TCF11
nuclear factor, erythroid 2-like 1 3,4-dihydroxyphenylethanol inhibits the reaction [Acrolein results in decreased expression of NFE2L1 protein] decreases expression
/ decreases reaction
protein 20938484
C005975 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) 3,4-dihydroxyphenylethanol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA] decreases reaction
/ increases expression
mRNA 22595400
C005975 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) 3,4-dihydroxyphenylethanol inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone] decreases reaction
/ increases chemical synthesis
/ increases expression
protein 22595400
C005975 5862 RAB2A
LHX
RAB2
RAB2A, member RAS oncogene family 3,4-dihydroxyphenylethanol results in increased expression of RAB2A mRNA increases expression
mRNA 12482581
C005975 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A 3,4-dihydroxyphenylethanol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased localization of and results in increased activity of RELA protein] decreases reaction
/ increases activity
/ increases localization
protein 22595400
C005975 6119 RPA3
REPA3
replication protein A3, 14kDa [Vitamin E co-treated with Quercetin co-treated with kaempferol co-treated with 3,4-dihydroxyphenylethanol] results in increased expression of RPA3 mRNA affects cotreatment
/ increases expression
mRNA 16797527
C005975 6401 SELE
CD62E
ELAM
ELAM1
ESEL
LECAM2
selectin E 3,4-dihydroxyphenylethanol inhibits the reaction [Lipopolysaccharides results in increased expression of SELE protein] decreases reaction
/ increases expression
protein 12615669
C005975 6773 STAT2
ISGF-3
P113
STAT113
signal transducer and activator of transcription 2, 113kDa [Vitamin E co-treated with Quercetin co-treated with kaempferol co-treated with 3,4-dihydroxyphenylethanol] results in decreased expression of STAT2 mRNA affects cotreatment
/ decreases expression
mRNA 16797527
C005975 7019 TFAM
MTTF1
MTTFA
TCF6
TCF6L1
TCF6L2
TCF6L3
transcription factor A, mitochondrial 3,4-dihydroxyphenylethanol inhibits the reaction [Acrolein results in decreased expression of TFAM mRNA] decreases expression
/ decreases reaction
mRNA 20938484
C005975 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor 3,4-dihydroxyphenylethanol inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] decreases reaction
/ increases expression
protein 12615669
17586618
C005975 7412 VCAM1
CD106
INCAM-100
vascular cell adhesion molecule 1 3,4-dihydroxyphenylethanol inhibits the reaction [Homocysteine results in increased expression of VCAM1 protein] decreases reaction
/ increases expression
protein 17586618
C005975 7412 VCAM1
CD106
INCAM-100
vascular cell adhesion molecule 1 3,4-dihydroxyphenylethanol inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 mRNA] decreases reaction
/ increases expression
mRNA 12615669
C005975 7412 VCAM1
CD106
INCAM-100
vascular cell adhesion molecule 1 3,4-dihydroxyphenylethanol inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein] decreases reaction
/ increases expression
protein 12615669
C005975 7412 VCAM1
CD106
INCAM-100
vascular cell adhesion molecule 1 3,4-dihydroxyphenylethanol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of VCAM1 protein] decreases reaction
/ increases expression
protein 12615669
C005975 7412 VCAM1
CD106
INCAM-100
vascular cell adhesion molecule 1 3,4-dihydroxyphenylethanol inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] decreases reaction
/ increases expression
protein 12615669
17586618

Related Disease

Diseases related to CTD interactions

4 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D003928 C005975 Diabetic Nephropathies therapeutic
19393637
D050171 C005975 Dyslipidemias therapeutic
19393637
D006943 C005975 Hyperglycemia therapeutic
19393637
D008107 C005975 Liver Diseases therapeutic
19393637